Values First Advisors Inc. Takes Position in Inozyme Pharma, Inc. (NASDAQ:INZY)

Values First Advisors Inc. purchased a new position in Inozyme Pharma, Inc. (NASDAQ:INZY) in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 13,898 shares of the company’s stock, valued at approximately $59,000.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Adage Capital Partners GP L.L.C. lifted its position in Inozyme Pharma by 30.3% in the third quarter. Adage Capital Partners GP L.L.C. now owns 5,537,500 shares of the company’s stock worth $23,258,000 after purchasing an additional 1,287,500 shares during the period. Pivotal bioVenture Partners Investment Advisor LLC boosted its position in shares of Inozyme Pharma by 22.8% during the 3rd quarter. Pivotal bioVenture Partners Investment Advisor LLC now owns 4,494,851 shares of the company’s stock valued at $18,878,000 after purchasing an additional 833,333 shares in the last quarter. Rock Springs Capital Management LP raised its holdings in shares of Inozyme Pharma by 7.4% in the 3rd quarter. Rock Springs Capital Management LP now owns 3,681,174 shares of the company’s stock worth $15,461,000 after purchasing an additional 253,090 shares in the last quarter. Eventide Asset Management LLC acquired a new stake in Inozyme Pharma during the third quarter valued at approximately $13,125,000. Finally, FMR LLC grew its position in Inozyme Pharma by 229.2% in the third quarter. FMR LLC now owns 2,465,232 shares of the company’s stock worth $10,354,000 after buying an additional 1,716,398 shares during the last quarter. 88.30% of the stock is currently owned by institutional investors.

Inozyme Pharma Stock Performance

INZY traded up $0.27 during trading on Thursday, hitting $7.66. The stock had a trading volume of 1,258,228 shares, compared to its average volume of 541,895. The company has a current ratio of 13.36, a quick ratio of 13.36 and a debt-to-equity ratio of 0.32. Inozyme Pharma, Inc. has a 12 month low of $2.69 and a 12 month high of $7.72. The company has a 50 day simple moving average of $5.77 and a 200-day simple moving average of $4.50. The firm has a market cap of $473.16 million, a PE ratio of -5.51 and a beta of 1.34.

Inozyme Pharma (NASDAQ:INZY) last announced its earnings results on Tuesday, March 12th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.04). Analysts expect that Inozyme Pharma, Inc. will post -1.48 EPS for the current year.

Analyst Ratings Changes

INZY has been the topic of a number of recent research reports. Wedbush restated an “outperform” rating and issued a $15.00 target price on shares of Inozyme Pharma in a report on Tuesday, March 12th. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of Inozyme Pharma in a research note on Wednesday, March 13th.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.